Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE of SEGMENT INFORMATION (Details)

v3.22.1
SCHEDULE of SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Apr. 30, 2022
Apr. 30, 2021
Apr. 30, 2022
Apr. 30, 2021
Oct. 31, 2021
Segment Reporting Information [Line Items]          
Net loss $ (3,588) $ (2,437) $ (7,467) $ (4,669)  
Total operating costs and expenses 3,589 2,437 7,469 5,183  
Less non-cash share-based compensation (1,681) (1,051) (4,036) (2,037)  
Operating costs and expenses excluding non-cash share based compensation expense 1,908 1,386 3,433 3,146  
Total Asset 32,797   32,797   $ 36,257
Cart Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Net loss (1,399) (1,446) (3,010) (2,406)  
Operating costs and expenses excluding non-cash share based compensation expense 759 935 1,427 1,492  
Total Asset 13,014   13,014   15,068
Cancer Vaccines [Member]          
Segment Reporting Information [Line Items]          
Net loss (1,423) (662) (2,780) (1,569)  
Operating costs and expenses excluding non-cash share based compensation expense 740 299 1,220 837  
Total Asset 12,680   12,680   13,276
Anti Viral Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Net loss (757) (310) (1,661) (791)  
Operating costs and expenses excluding non-cash share based compensation expense 402 138 774 409  
Total Asset 6,883   6,883   7,368
Other [Member]          
Segment Reporting Information [Line Items]          
Net loss (9) (19) (16) 97  
Operating costs and expenses excluding non-cash share based compensation expense 7 $ 14 12 $ 408  
Total Asset $ 220   $ 220   $ 545